I G H -D O S E I N T R A V E N O U S gammaglobulin (IV-
IgG) is reported useful in alleviating a variety of immune-mediated blood cell disease^.'.^ Not only have autoimmune disorders been treated, but treatment of alloimmune-mediated cell processes has also been attempted. In particular, the treatment of autoimmune thrombocytopenia has been studied.'^^ Use of high-dose IgG in treating platelet transfusion refractoriness in alloimmunized thrombocytopenic patients has been studied with conflicting results in nonrandomized st~dies.',~ W e describe a randomized, blinded, placebo-controlled study of IV-IgG in alloimmunized thrombocytopenic patients requiring platelet transfusions. W e measured the effect of IV-TgG by administering incompatible platelets from the same donor before and after treatment. Serial antiplatelet antibodies were measured to determine any effect of treatment. Table 1 for clinical information) were enrolled in the study who had HLA antibodies by lymphocytotoxicity testing and who were failing platelet transfusions although they had no sepsis, splenomegaly, disseminated intravascular coagulation, or serious bleeding. Patients were excluded if they failed HLA-identical or closely matched platelet transfusions. Each patient consented to the protocol approved by the Johns Hopkins Joint Committee on Clinical Investigation.
MATERIALS AND METHODS

Patient eligibility. Patients (see
The study was a randomized, double-blinded, placebo-controlled trial in which the patient received incompatible platelet transfusions collected by platelet pheresis from the same donor before and after study drug. After patients received the HLA-incompatible transfusion, their platelet counts were obtained at 1, 6, and 24 hours. For 5 days after this transfusion, the patient randomly received either placebo or IV-IgG. The saline placebo had 1 g human albumin added per liter to resemble a solution of IgG. After the 5 days, platelets were collected from the same donor and transfused to the patient. Our initial plan was to enroll 10 patients in each group; however, because of the unavailability of eligible patients and the poor 24-hour survival of transfused platelets in nearly all patients, the study was terminated early and the blind was broken.
Platelets were collected with a Fenwal CS 3000 or Haemonetics model 30. Platelet donors were selected after having failed to give a satisfactory 1-hour corrected count increment and/or 24-hour survival. The recipient plasma was also cross-
Study design.
Platelet transfusion. matched with the donor platelets. All platelet transfusions were A B 0 compatible, with platelet counts performed on all units of platelets.
The IV-IgG (Gammagard) was supplied by Hyland Division of Baxter Healthcare, Glenside, CA. To maintain the blinded study, the lyophilized product was reconstituted by a pharmacist and administered at a dose of 400 mg/kg for 5 consecutive days. The volume of placebo was equivalent to the appropriate volume of IV-IgG adjusted for the patient's weight. This formulation of IV-IgG is produced from pooled plasma, undergoes Cohn fractionation, and chromatographic purification. Of the 4 to 5 g/100 mL protein per vial 96% is gammaglobulin. Ofthegammaglobulin content at least 92% is IgG monomer. The reconstituted product contains 0.3 mol/L glycine as a stabilizing agent.
Platelet crossmatching studies were performed with a radiolabeled antiglobulin test, with results expressed as an index (>2 was scored as positive).' Blood samples were collected on day 0 through day 5 of study drug administration and 2 weeks after termination of the study; "Cr release assay was also used to test the patient's serum against donor platelets.'" A panel of 20 HLA-typed donors was used for lymphocytotoxicity testing. Results are expressed as a percentage and referred to as antibody level. Antibodies to platelet-specific antigens were measured with a solidphase assay."
We measured posttransfusion platelet counts 1, 6, and 24 hours after transfusion. The corrected count increment (CCI) was calculated with the following formula: CCI = post-platelet count -pre-platelet count x surface area in m2/ number of platelets x 10." Statistical methods. Differences between the mean values of baseline and response variables for the placebo and immunoglobulin group were tested for statistical significance by t test. Analogous nonparametric Wilcoxon test and median tests were used when distributional assumptions were in doubt. In addition, standard transformations such as the log transformation for skewed variables and arcson transformation for percentages were used.
Dosage and administration.
Platelet antibody studies. The principal statistical endpoint of the study was the poststudy 1-hour CCI. In addition to the posttreatment platelet CCI, we also examined the difference between the 1-hour poststudy platelet increment and the 1-hour prestudy platelet increment. These responses were adjusted for the possible confounding effects of baseline characteristics with a simple linear regression model. Group comparisons were made with this model in a multivariate analysis. Specifically, the model adjusted for baseline antibody level and pretreatment hematocrit and platelet count. For the 1-hour poststudy platelet increment endpoint, the model also adjusted for the 1 hour prestudy platelet count. All P values reported are two-sided.
By the above formula for calculating CCIs, our criteria for an acceptable 1-hour increment is greater than 7,500 and greater than 4,500 at 24 hours. ' The grade of HLA match was classified as follows: A match, four-antigen match for HLA A and B antigens; and BU match, two (B2U) or three donor HLA antigens (BlU) identical to the recipient, with blanks in the balance of the phenotype; BX match, serologic crossreactivity of HLA antigens, with a BlX or B2X having one or two antigens selectively mismatched for cross-reactive HLA antigens; C match, mismatch of one donor antigen; and D match, mismatch of two or more antigens.
Qualitative definition of platelet response.
Definition of platelet HLA match grade.
RESULTS
All patients were moderately transfused with blood products (range was 4 to 42 for red blood cell [RBC] units transfused and 28 to 212 for platelets transfused). As shown in Table 1 , all patients had HLA antibodies. The degree of HLA reactivity on a 20-cell panel ranged from 30% to 100% and did not change during the treatment course or after 2-week follow-up. Platelet cross-matching done on samples from day 0 to 5 were also unchanged. The plasma of all patients except patient 10 had detectable antibody against the transfused platelets by radiolabeled antiglobulin test and were reactive in a 5'Cr release assay. In a solid-phase immobilized glycoprotein IIB-IIIA assay, no antibodies to alloantigens (PLA, BAK, PEN) performed on this complex were present. The degree of HLA match between the donor and patients varied between BU and D matches, with several pairs being BX grades of match. Table 2 shows the results of giving IV-IgG or placebo to the patients. The CCIs are shown 1, 6, and 24 hours after transfusion. For comparison, the transfusion outcomes from the best available HLA-matched transfusions are shown. A good response to these transfusions insured that nonimmune causes of shortened platelet survival were not present. In 10 of the 12 patients, prestudy CCIs a t 1 hour were less than 2,500. Although in two patients (patients 6 and 11) 1-hour survival was adequate, no survival was noted a t 24 hours. Seven patients were randomized to receive IV-IgG, and five received placebo. Fiveof the patients (patients 6,7,9, 10, and 12) receiving IV-IgG had an improvement in CCIs in comparison to the pretreatment platelet transfusion outcome. None of the placebo patients achieved satisfactory platelet increments. Three IV-IgG-treated patients achieved a satisfactory 1-hour CCI, but none of these patients showed improved 24-hour survival. In only one patient (patient 6) was platelet survival improved at 24 hours. This patient differed in that the pretreatment 1-hour CCI was within acceptable levels, but transfused platelets did not have good 24-hour platelet survival. In patient 12, 1-to 6-hour platelet survival was improved after IV-IgG but 24-hour survival was poor.
Too few patients were studied to determine whether there was a relationship to the degree of HLA match and responsiveness to IV-IgG. After IV-IgG, four patients (patients 6, 9, 7, and 12) receiving HLA-mismatched platelets had improvement in platelet increments to levels comparable with HLA-identical platelet transfusions. Patient 8, who received an HLA-identical transfusion (B2U), had no improvement in 1 -hour platelet recovery.
No patients in the placebo group experienced adverse reactions, whereas three of the IV-IgG-treated patients had fever or chills. This difference was not statistically significant. There were no significant differences in pretreatment antibody levels or platelet counts in the two groups. The mean 1-hour posttreatment CCI in the IV-IgG group of 8,413 was significantly greater than the placebo group's mean CCI of 1,056 (P < .007 by t test). We also examined the difference between the 1-hour CCI before and after treatment. Again the IV-IgG treatment was associated with significantly improved mean 1-hour CCI (5,377 v 969 in placebo) (P < .02). If the nonparametric Wilcoxon test was used, the post IV-IgG treatment 1-hour CCI was significantly increased as compared with the placebo (P < .009).
DISCUSSION
During induction chemotherapy for leukemia, 20% to 40% of patients may become alloimmunized to HLA antigens, leading to platelet transfusion refractoriness and necessitating use of HLA-matched platelets.'**" Because of the polymorphism of the HLA system, HLA-compatible platelets may not be available, leading to difficulty in managing alloimmunized patients.
In this difficult situation, a variety of approaches have been tried with variable success. The usefulness of IV-IgG in treating patients with autoimmune thrombocytopenia suggests that IV-IgG may be useful in alloantibody-mediated platelet destruction. In an uncontrolled series of 11 patients, Schiffer et a1 demonstrated no improvement in one hour corrected count increments when 400 mg/kg of IV-IgG was used for 5 days.' This group subsequently studied seven more patients using another formulation of IV-IgG and again observed no benefit.14 In another nonrandomized series, Ziegler et a1 showed a beneficial effect of IV-IgG on platelet survival.' Decreased levels of antiplatelet antibodies were also noted in this report.
Although we observed improved 1-hour CCIs, only one patient had improved platelet survival a t 24 hours. Therefore, with the transfusion regimen used, the clinical benefit from IV-IgG was not clearly demonstrated. If more frequent platelet transfusions were administered, the platelet count perhaps could be maintained above a level sufficient to prevent bleeding or allow safe performance of invasive procedures. Studies documenting whether this approach may have clinical benefit are needed.
From the small number of patients we studied, it is unclear whether IV-IgG is more efficacious if more closely matched platelets are used. We observed some improvement in 1-hour CCIs in three patients who received HLA-mismatched platelets, whereas a closely HLA-matched transfusion gave poor results. Future studies using platelet transfusions stratified by the degree of HLA matching may clarify this question.
In conclusion, IV-IgG at a dose of 400 mg/kg for 5 days may lead to improved 1-hour platelet recovery but not 24-hour survival, resulting in a suboptimal treatment effect. Routine administration of IV-IgG cannot be recommended as a replacement for closely HLA-matched platelet transfusions. Additional clinical trials are needed to determine whether more frequent platelet transfusions in combination with IV-IgG may lead to clinical benefit in patients without compatible platelet donors.
